Back to results
US 2026/0294906 A1Published application
Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha
AssigneeSanofi
InventorsOhn CHOW, Nassr NASSR, Mai Anh NGUYEN, Laurent PERRIN
Life of this patent
Estimating the term…
Abstract
Provided herein are treatments for psoriasis, wherein a human subject is administered a 400 mg daily dose of Compound 1 or a pharmaceutically acceptable salt thereof.
Claims11
A compound for use in a method of treating psoriasis in a human subject, wherein the compound is (7R,14R)-11-[2-(1-aminocyclobutyl)pyrimidin-5-yl]-1-(difluoromethoxy)-6-methyl-6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one (Compound 1):
- or a pharmaceutically acceptable salt thereof, wherein the subject has mild to moderate psoriasis, and wherein the method comprises administering to the subject a daily dose of about 400 mg of the compound (calculated as the free base).
Dependencies are inferred from the claim text.